资源描述：
《喜炎平佐治小儿支原体肺炎相关血清炎性因子检测及其机制分析》由会员上传分享，免费在线阅读，更多相关内容在工程资料-天天文库。
1、喜炎平佐治小儿支原体肺炎相关血清炎性因子检测及其机制分析［摘要］目的探讨喜炎平辅佐治疗小儿支原体肺炎的临床疗效及作用机制。方法方便选取2014年1月一2016年12月该院收治的58例小儿支原体肺炎患儿为研究对象，全部患儿均行呼吸道隔离、祛痰、平喘等一般治疗，随机将入选病例分为两组。对照组29例，予以患儿阿奇霉素；实验组29例，患儿在对照组治疗基础上加用喜炎平。治疗前后,检测两组血清TNF-a、IL-6、IL-8水平，对比观察两组临床疗效。结果实验组治疗总有效率(100.0%)显著高于(P<0.05)o连续治疗5d后，实验组TNF(24.2士9
2、.5)pg/mL,IL-6(17.2±4.3)pg/mL,IL-8(7.9±2.2)pg/mL,3项指标均显著低于对照组，差异有统计学意义(P<0.05)o结论喜炎平辅佐阿奇霉素治疗小儿支原体肺炎的临床效果显著，可能机制为喜炎平调控炎性因子、改善机体免疫功能。［关键词］小儿支原体肺炎；喜炎平；血清炎性因子；治疗机制［中图分类号］R725［文献标识码］A［文章编号］1674-0742(2017)05(c)-0143-03[Abstract]ObjectiveTodiscusstheclinicalcurativeeffectandmechani
3、smofxiyanpingadjunctivetreatmentofofmycoplasmapneumoniainchildren.Methods58caseschildrenwithmycoplasmapneumoniaadmittedandtreatedinourhospitalfromJanuary2014toDecember2016wereconvenientlyselectedandallpatientsadoptedthegeneraltreatmentofisolationoftherespiratorytract,expect
4、orantandantiasthmatictherapy,andthecasesweredividedintotwogroupswith29casesineach,thecontrolgroupadoptedtheazithromycin，whiletheexperimentalgroupaddedthexiyanpingonthebasisofthecontrolgroup,andtheserumTNFIL-6,IL-8levelsofthetwogroupsweretestedbeforeandaftertreatment,andthec
5、linicalcurativeeffectofthetwogroupswasobservedandcompared.ResultsThetotaltreatmenteffectiverateintheexperimentalgroupwasobviouslyhigherthanthatinthecontrolgroup,whichwas100.0%intheexperimentalgroup(P<0.05),aftertheconsecutive5days,theTNF・a,IL-6,IL-8levelsintheexperimentgrou
6、pwererespectively(24.2±9.5)pg/mL,(17.2±4.3)pg/mLand(7.9±2.2)pg/mL,whichwereobviouslylowerthanthoseinthecontrolgroup,andthedifferenceswerestatisticallysignificant(P<0.05).ConclusionTheclinicaleffectofxiyanpingadjunctivetreatmentofmycoplasmapneumoniainchildrenisobvious,andthe
7、possiblemechanismistheadjustmentofinflammatoryfactorsbyxiyanpingandimprovementoforganimmunefunction.[Keywords]MycoplasmapneumoniainchiIdren；Xiyanping；Seruminflammatoryfactor；Treatmentmechanism肺炎支原？w肺炎（MPP）是支原体（MP）感染所引起的间质性肺炎和毛细支气管炎样改变，属临床常见非典型肺炎。MP是小儿呼吸系统感染的重要病原菌，由此引起的小儿MPP
8、约占儿童社区获得性肺炎的30%[1]o小儿MPP症状多轻重不一，重症者预后差，甚至可导致死亡，需儿科医师予以高度重视。阿奇霉素是小儿MPP首选治疗药物，但近年有研究
